Silo Pharma to Present at IPAC-RS 2026 Nasal Innovation Forum, Highlighting Progress of PTSD Treatment SPC-15

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. The forum brings together experts in nasal drug development, providing a platform for Silo to discuss its ongoing work with SPC-15, a novel intranasal formulation designed for the treatment of post-traumatic stress disorder (PTSD).

CEO Eric Weisblum emphasized the importance of the event, stating that it offers a valuable opportunity to engage with leading professionals in the field as the company continues to advance SPC-15's nose-to-brain approach to targeted drug delivery. This strategy aims to enhance the therapeutic efficacy of the treatment by directly targeting the central nervous system, potentially offering a faster and more effective option for patients suffering from PTSD.

The company's participation is supported by recent preclinical data demonstrating the stability and quality of the SPC-15 formulation and device. Results showed that the product met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data was consistent with long-term data, indicating the robustness of the formulation.

These findings are critical as Silo Pharma progresses toward clinical development. The data not only validate the manufacturing process but also support the potential for a viable commercial product. The company's focus on underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases aligns with a growing need for innovative therapies in these areas.

Silo Pharma's portfolio includes other promising programs, such as SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company collaborates with leading universities and laboratories to advance its research. This collaborative approach enhances its capability to bring novel treatments to market.

The IPAC-RS forum is a significant venue for Silo Pharma to showcase its progress and network with potential partners and investors. As the company continues to develop its pipeline, participation in such events is crucial for gaining industry insights and fostering relationships that could accelerate development.

For more information about Silo Pharma and its programs, visit the company's website at silopharma.com.